Global nav1.7 knockout mice and uses

a technology of nav1.7 and mice, applied in the field of global nav1.7 knockout mice and uses, can solve the problem of complete inability of otherwise healthy individuals to sense any form of pain, and achieve the effects of preventing flinching behavior, no flinching or licking behavior, and robust flinching behavior

Inactive Publication Date: 2012-07-19
AMGEN INC
View PDF1 Cites 35 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0032]Most significantly, we show in Example 5 herein that a NaV1.7 activator, e.g., veratridine dosed at 1 microgram, produces no flinching or licking behavior when injected into the paw of global Nav1.7− / − mice, whereas this same 1 microgram dose produces a robust flinching behavior in wild type mice. Pharmacological block of NaV1.7 should achieve the same effect, since pre-administration to wild type mice of mexiletine (which blocks NaV1.7 as well as all other sodium channels) prevents the flinching behavior evoked by the 1-microgram dose of veratridine. Accordingly, in preclinical studies, challenge with a sodium channel activator is a useful test of whether a given compound administered to a living animal is blocking NaV1.7. Furthermore, this test could be used clinically to determine proper dosing of a test NaV1.7 inhibitor to treat a clinical pain syndrome. A proper clinical dose would be one that prevents a painful response to administration of a sodium channel activator.

Problems solved by technology

Loss-of-function mutations of the SCN9A gene result in a complete inability of an otherwise healthy individual to sense any form of pain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Global nav1.7 knockout mice and uses
  • Global nav1.7 knockout mice and uses
  • Global nav1.7 knockout mice and uses

Examples

Experimental program
Comparison scheme
Effect test

example 1

Backcrossing and Outcrossing

[0231]Because of the reported neonatal lethality of NaV1.7 KO animals (heterozygous Nav1.7+ / − mice from Deltagen, San Mateo, Calif.: B6.129P2-Scn9 atm1Dgen / J backcrossed at least 8 generations to C57BL / 6) due to an apparent failure to feed (Nassar et al., 2004), we outcrossed these animals onto a CD1 background to add vigor to the line, as well as a separate backcross onto a BALB / c line to create a congenic line (first breeding pair received in May 2011). (See, FIG. 1A-B).

[0232]No significant differences were noted in Scn9a-CD1 KO or Scn9a-Balbc KO animals. We refer to these animals as NaV1.7 KO and specify the strains when required. All data displayed herein were collected on single out- and backcross. Further backcrosses (for BALB / c line only) are currently being performed, thus far results obtained were identical on a N4 backcross generation. No further increase in survival was observed. The final outcome of the backcrossing has yet to be determined up...

example 2

Preparation of Artificial Mouse Milk (AMA)

[0245]The procedure and composition of the artificial mouse milk prepared was modeled closely after that described by Yajima and co-workers and by Auestad and co-workers. (Yajima, M, et al., A Chemically Derived Milk Substitute that is Compatible with Mouse Milk for Artificial Rearing of Mouse Pups” Exp. Amin. 55(4), 391-397, (2006); Auestad, N, et al., Milk-substitutes comparable to rat's milk; their preparation, composition and impact on development and metabolism in the artificially reared rat, Br. J. Nutr. 61: 495-518 (1989)).

[0246]Reagents and Procedure. Reagents used, including source, amounts used, solvents and amounts used, and miscellaneous comments are listed in Table 3 (below).

[0247]Procedure. Step 1: Sodium hydroxide was weighed and transferred to a 10-L beaker. Distilled Water (1.3 L) was added and an overhead stirrer was put in place. Potassium hydroxide was weighed and added to this solution, as were L-serine, L-cystine and L-...

example 3

Genotyping

[0250]The following primers were used to genotype all animals in the colony: Forward Scn9a 5′ AGA CTC TGC GTG CTG CTG GCA AAA AC 3′ (SEQ ID NO:1); Reverse Scn9a 5′ CGT GGA AAG ACC TTT GTC CCA CCT G 3′ (SEQ ID NO:2) and Forward Neomycin 5′ GGG CCA GCT CAT TCC TCC CAC TCA T 3′(SEQ ID NO:3). These primers gave rise to an endogenous band of 267 base pairs (Forward Scn9a+Reverse Scn9a) or a targeted band of 389 base pairs (Forward Neomycin+Reverse Scn9a). PCR cycling conditions were as follows: (1) 95° C. for 7 minutes, followed by 35× cycles of (2)-(4) below, followed by (5)-(6):

[0251](2) 96° C. for 10 seconds;

[0252](3) 60° C. for 30 seconds;

[0253](4) 72° C. for 1.5 minutes,

[0254](5) 72° C. for 7 minutes;

[0255](6) cool to 4° C.

[0256]The genotyped patterns were as follows:

[0257]WT or + / +=endogenous (E) band only

[0258]HET or + / −=endogenous (E)+targeted (T) bands

[0259]KO or − / −=targeted (T) band only

[0260]DNA concentrations ranging between ˜25 ng up to 1 μg were originally tested...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
holding voltageaaaaaaaaaa
repolarization voltageaaaaaaaaaa
Login to view more

Abstract

A viable global NaV1.7− / − knockout mouse is disclosed, and a breeding colony of global NaV1.7− / − knockout mice. Also disclosed are an isolated mouse gamete that does not encode a functional NaV1.7− / −, produced by the NaV1.7− / − knockout mouse; an isolated NaV1.7− / − mouse cell, or a progeny cell thereof, isolated from the NaV1.7− / − knockout mouse; and a primary cell culture or a secondary cell line and a tissue or organ explant or culture thereof derived from the NaV1.7− / − knockout mouse. Disclosed also are a hybridoma, wherein the hybridoma was originally formed from the fusion of the isolated NaV1.7− / − mouse cell mouse cell and a myeloma cell, and a method of making an antibody. Also disclosed are assays useful for screening prospective NaV1.7 inhibitors and dose ranging a test NaV17 inhibitor compound, which were validated using the NaV1.7− / − knockout mouse.

Description

[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 433,910, filed Jan. 18, 2011, and U.S. Provisional Application No. 61 / 557,877, filed Nov. 9, 2011, both of which are hereby incorporated by reference in their entireties.FIELD OF THE INVENTION[0002]The instant application contains an ASCII “txt” compliant sequence which serves as both the computer readable form (CRF) and the paper copy required by 37 C.F.R. Section 1.821(c) and 1.821(e), and is hereby incorporated by reference in its entirety. The name of the “txt” file created on Jan. 17, 2012, is: A-1588-US-NP-SeqList011812.5T25.txt, and is 2 kb in size.[0003]Throughout this application various publications are referenced within parentheses or brackets. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains.BACKGROUND OF THE INVENTION[0004]1. Field of the In...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A01K67/027C07K1/00C12N5/20C12N5/10C12N5/18
CPCA01K67/0276A01K2217/077A01K2227/105C12N15/8509A61K49/0008C07K16/00A01K2267/03A01K67/027C12N5/0609C12N5/061
Inventor GINGRAS, JACINTHE
Owner AMGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap